Risk Classification Rules for Medical Devices in Australia

1. Key takeaways

The classification of non-IVD medical devices in Australia applies the 28 classification rules in Schedule 2 plus one interpretation clause, with four classes: Class I, IIa, IIb, and III. There is no longer an independent AIMD class; active implantable devices have been absorbed into Class III since 25 November 2021. The classification outcome directly determines the conformity assessment route, the likelihood of audit, and the applicable fee tier, which makes it one of the highest-leverage determinations in the entire Australian pathway. A single misapplied rule can move a product across a class boundary and change the evidentiary expectations, the assessment body options, and the cost base simultaneously. Classification should therefore be performed as a documented, rule-by-rule exercise rather than as an inference from precedent products, however similar those products may appear.

2. Legal basis

1. Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883): the legal basis for classification is regulation 3.1 (invoking section 41DB of the Therapeutic Goods Act 1989), regulation 3.2, and regulation 3.3; non-IVD devices apply Schedule 2.
2. Structure of Schedule 2: Part 1 interpretation (cl 1.1); Part 2 non-invasive devices (cl 2.1, 2.2, 2.2A, 2.3, 2.4); Part 3 invasive and implantable devices (cl 3.1–3.4); Part 4 active devices (cl 4.1–4.8); Part 5 special rules (cl 5.1–5.11); totalling 28 classification rules plus 1 interpretation clause.
3. Classification rule 5.5: replaced in its entirety by the Therapeutic Goods Legislation Amendment (2024 Measures No. 2) Regulations 2024 (registration number F2024L00686), applying to new applications from 1 July 2024 and to transitional devices from 1 July 2026; the current text covers medical devices containing non-viable animal tissue, cells, or their derivatives (Sch 2 cl 5.5(1)–(3)), classified as Class III, excluding tissue or cells derived from hair or wool, sintered hydroxyapatite, and tallow derivatives, and excluding devices that only contact intact skin.
4. Accompanying obligations: F2024L00686 added the transitional provision regulation 11.77 and the labelling disclosure obligation in regulation 5.12 (disclosure that the device contains non-viable animal tissue or cells).
5. Absorption of AIMD into Class III: Schedule 2, items 5.7(1)–(3); implemented by Schedule 1 of the Therapeutic Goods Legislation Amendment (2019 Measures No. 1) Regulations 2019 (F2019L01660), titled “Reclassification of medical devices”, which took effect on 25 November 2021.
6. Materials of microbial or recombinant origin are no longer within rule 5.5; risk control for them is now carried by Essential Principles Schedule 1, item 8.2, together with the Schedule 3 conformity assessment pathways.

3. Expert insights

Insight 1: Two versions of rule 5.5 coexisted in the same market at the same time. The new rule applied to new applications from 1 July 2024, while transitional devices had until 1 July 2026. Between 1 July 2024 and 30 June 2026, the market therefore operated under two parallel readings of rule 5.5. That window closed on 1 July 2026, and companies still managing animal-derived products under the old reading need to complete their review. Periods of dual applicability are inherently error-prone: internal documents, supplier files, and previous submissions may all reflect the superseded text, and reconciling them requires a deliberate sweep rather than an assumption that the newest documents are the only ones in circulation.

Insight 2: The removal of microbial and recombinant materials from rule 5.5 is not a relaxation. Once moved out of the classification rule, their risk control was transferred to Essential Principles item 8.2 and to the conformity assessment pathways. The class assignment may drop, but the obligation to comply with the Essential Principles does not, and the labelling disclosure duty in regulation 5.12 still applies where it is engaged. The apparent simplification of the classification rule therefore masks a redistribution of obligations rather than their reduction, and teams that read the amendment as a downgrade risk leaving the corresponding evidence unprepared at assessment.

Insight 3: The absorption of AIMD into Class III changed the fee and audit tiers. Active implantable devices no longer form a separate class, which means their annual fees, application fees, and mandatory audit requirements now sit at the Class III tier. Projects whose documents still say “Class AIMD” may be running their cost base on the wrong footing. Beyond budgeting, the change also affects planning, because the Class III tier carries the heaviest conformity assessment expectations in the Schedule 2 framework, and timelines calibrated to a lighter tier will systematically undershoot.

4. Practical recommendations

1. When issuing a classification determination, work through every applicable rule in Schedule 2 in sequence, and do not substitute a prior classification of a similar product for a rule-by-rule determination; precedent is a check, not a method.
2. For products containing animal-derived, microbial, or recombinant materials, check three things together at review: the current text of rule 5.5, Essential Principles item 8.2, and the labelling disclosure obligation in regulation 5.12.
3. For transitional devices included in the Register before 1 July 2024, set 1 July 2026 as the mandatory review deadline and treat it as a hard gate in the compliance calendar rather than a target.
4. Replace every instance of “Class AIMD” with the Class III designation across the document set, and re-verify the applicable fee tier at the same time so that documents and budgets move together.

5. Verification checklist

• □ Every applicable rule in Schedule 2 has been applied in sequence, with a written classification conclusion
• □ Whether the device contains non-viable animal tissue, cells, or derivatives has been confirmed, and the current cl 5.5 applied
• □ Transitional devices have a review checkpoint set for 1 July 2026
• □ Products of microbial or recombinant origin have been checked against Essential Principles item 8.2
• □ The labelling disclosure obligation in regulation 5.12 has been verified
• □ “Class AIMD” has been removed from the documents and the fee tier re-verified

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages TGA inclusion and ARTG listing applications, coordinates conformity assessment evidence, and supports post-market vigilance obligations. Business enquiries: info@grzan.cn